
The rate of decline in the use of atypical antipsychotics in outpatients with dementia accelerated following a black box warning issued by FDA, according to "Trends in Antipsychotic Use in Dementia 1999-2007," a multicenter study of national Veterans Affairs data that appeared in the Archives of General Psychiatry.